低剂量白细胞介素-2治疗系统性红斑狼疮
Low-dose interleukin-2 therapy in systemic lupus erythematosus.
作者信息
La Cava Antonio
机构信息
Department of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA.
出版信息
Rheumatol Immunol Res. 2023 Sep 27;4(3):150-156. doi: 10.2478/rir-2023-0021. eCollection 2023 Sep.
Abstract
In systemic lupus erythematosus (SLE), T regulatory cells (T) contribute to the inhibition of autoimmune responses by suppressing self-reactive immune cells. Interleukin (IL)-2 plays an essential role in the generation, function and homeostasis of the T and is reduced in SLE. Several clinical studies, including randomized trials, have shown that low-dose IL-2 therapy in SLE patients is safe and effective and can reduce disease manifestations. This review discusses the rationale for the use of low-dose IL-2 therapy in SLE, the clinical responses in patients, and the effects of this therapy on different types of T cells. Considerations are made on the current and future directions of use of low-dose IL-2 regimens in SLE.
摘要
在系统性红斑狼疮（SLE）中，调节性T细胞（Treg）通过抑制自身反应性免疫细胞来抑制自身免疫反应。白细胞介素（IL）-2在Treg的产生、功能和稳态中起关键作用，且在SLE中水平降低。包括随机试验在内的多项临床研究表明，SLE患者接受低剂量IL-2治疗是安全有效的，且可减轻疾病表现。本文综述讨论了在SLE中使用低剂量IL-2治疗的理论依据、患者的临床反应以及该疗法对不同类型T细胞的影响。同时对SLE中低剂量IL-2治疗方案的当前及未来应用方向进行了探讨。
相似文献
1
Low-dose interleukin-2 therapy in systemic lupus erythematosus.
Rheumatol Immunol Res. 2023 Sep 27;4(3):150-156. doi: 10.2478/rir-2023-0021. eCollection 2023 Sep.
2
Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus.
Front Immunol. 2023 Sep 12;14:1230264. doi: 10.3389/fimmu.2023.1230264. eCollection 2023.
3
T Cells, Interleukin-2 and Systemic Lupus Erythematosus-From Pathophysiology to Therapy.
Cells. 2022 Mar 12;11(6):980. doi: 10.3390/cells11060980.
4
Targeting Regulatory T Cells to Treat Patients With Systemic Lupus Erythematosus.
Front Immunol. 2018 Apr 17;9:786. doi: 10.3389/fimmu.2018.00786. eCollection 2018.
5
Allogeneic cord blood regulatory T cells decrease dsDNA antibody and improve albuminuria in systemic lupus erythematosus.
Front Immunol. 2023 Sep 5;14:1217121. doi: 10.3389/fimmu.2023.1217121. eCollection 2023.
6
Low-dose interleukin-2 therapy: a promising targeted therapeutic approach for systemic lupus erythematosus.
Curr Opin Rheumatol. 2023 Mar 1;35(2):98-106. doi: 10.1097/BOR.0000000000000924. Epub 2022 Dec 22.
7
Low-dose IL-2 therapy limits the reduction in absolute numbers of peripheral lymphocytes in systemic lupus erythematosus patients with infection.
Curr Med Res Opin. 2022 Jun;38(6):1037-1044. doi: 10.1080/03007995.2022.2065145. Epub 2022 Apr 26.
8
Low-dose IL-2 therapy in autoimmune diseases: An update review.
Int Rev Immunol. 2024 May;43(3):113-137. doi: 10.1080/08830185.2023.2274574. Epub 2023 Oct 26.
9
Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus.
Ann Rheum Dis. 2016 Jul;75(7):1407-15. doi: 10.1136/annrheumdis-2015-207776. Epub 2015 Aug 31.
10
Retrospective analysis of low-dose interleukin-2 therapy on chronic autoimmune thyroid disease with concurrent systemic lupus erythematosus.
Ann Med. 2023;55(2):2238600. doi: 10.1080/07853890.2023.2238600.
引用本文的文献
1
CD2-targeted nanoparticles encapsulating IL-2 induce tolerogenic Tregs and TGF-β-producing NK cells that stabilize Tregs for long-term therapeutic efficacy in immune-mediated disorders.
Front Immunol. 2025 Jul 29;16:1587237. doi: 10.3389/fimmu.2025.1587237. eCollection 2025.
2
Regulatory T cell therapy in autoimmune liver disease and transplantation.
JHEP Rep. 2025 Mar 12;7(8):101394. doi: 10.1016/j.jhepr.2025.101394. eCollection 2025 Aug.
3
Efficacy and Safety of Low-Dose Interleukin-2 Therapy in Systemic Lupus Erythematosus: A Systematic Review.
Cureus. 2025 May 1;17(5):e83323. doi: 10.7759/cureus.83323. eCollection 2025 May.
4
Directed disruption of IL2 aggregation and receptor binding sites produces designer biologics with enhanced specificity and improved production capacity.
Comput Struct Biotechnol J. 2025 Mar 4;27:1112-1123. doi: 10.1016/j.csbj.2025.03.002. eCollection 2025.
5
Preclinical characterization of MTX-101: a novel bispecific CD8 Treg modulator that restores CD8 Treg functions to suppress pathogenic T cells in autoimmune diseases.
Front Immunol. 2024 Nov 4;15:1452537. doi: 10.3389/fimmu.2024.1452537. eCollection 2024.
6
Cutting Edge: Low-dose Recombinant IL-2 Treatment Prevents Autoantibody Responses in Systemic Lupus Erythematosus via Regulatory T Cell-independent Depletion of T Follicular Helper Cells.
J Immunol. 2024 Oct 15;213(8):1053-1060. doi: 10.4049/jimmunol.2400264.
7
Nanoparticles loaded with IL-2 and TGF-β promote transplantation tolerance to alloantigen.
Front Immunol. 2024 Jul 26;15:1429335. doi: 10.3389/fimmu.2024.1429335. eCollection 2024.
本文引用的文献
1
Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial.
Lancet Rheumatol. 2019 Sep;1(1):e44-e54. doi: 10.1016/S2665-9913(19)30018-9. Epub 2019 Aug 28.
2
The Dawn of a New Era of Therapies in Systemic Lupus Erythematosus.
Rheumatol Immunol Res. 2020 Dec 1;1(1):31-37. doi: 10.2478/rir-2020-0005. eCollection 2020 Dec.
3
Nanoparticle-mediated Delivery of IL-2 To T Follicular Helper Cells Protects BDF1 Mice from Lupus-like Disease.
Rheumatol Immunol Res. 2021 Dec 15;2(3):185-193. doi: 10.2478/rir-2021-0024. eCollection 2021 Sep.
4
Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial.
Ann Rheum Dis. 2022 Dec;81(12):1685-1694. doi: 10.1136/ard-2022-222501. Epub 2022 Aug 16.
5
Emerging mechanisms and applications of low-dose IL-2 therapy in autoimmunity.
Cytokine Growth Factor Rev. 2022 Oct;67:80-88. doi: 10.1016/j.cytogfr.2022.06.003. Epub 2022 Jun 30.
6
Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus.
J Transl Autoimmun. 2022 Mar 28;5:100152. doi: 10.1016/j.jtauto.2022.100152. eCollection 2022.
7
Low-dose IL-2 therapy invigorates CD8+ T cells for viral control in systemic lupus erythematosus.
PLoS Pathog. 2021 Oct 7;17(10):e1009858. doi: 10.1371/journal.ppat.1009858. eCollection 2021 Oct.
8
Low-Dose Interleukin-2 as an Alternative Therapy for Refractory Lupus Nephritis.
Rheumatol Ther. 2021 Dec;8(4):1905-1914. doi: 10.1007/s40744-021-00381-1. Epub 2021 Oct 7.
9
Strategies to Use Nanoparticles to Generate CD4 and CD8 Regulatory T Cells for the Treatment of SLE and Other Autoimmune Diseases.
Front Immunol. 2021 Jun 15;12:681062. doi: 10.3389/fimmu.2021.681062. eCollection 2021.
10
Nanoparticles Engineered as Artificial Antigen-Presenting Cells Induce Human CD4 and CD8 Tregs That Are Functional in Humanized Mice.
Front Immunol. 2021 May 26;12:628059. doi: 10.3389/fimmu.2021.628059. eCollection 2021.
Zotero 插件